182 results
Page 3 of 10
8-K
EX-10.1
qpqehne0ceo2td
22 Mar 22
Aravive Appoints Scott Dove, Ph.D., as Chief Operating Officer
4:06pm
424B3
3p55v6fnd
19 Jan 22
Prospectus supplement
4:05pm
8-K
EX-4.1
buz2l9g2x eb6n
4 Jan 22
Entry into a Material Definitive Agreement
6:02am
8-K
pa5uj1jongvb3ieofij
10 Sep 21
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
EX-10.1
kagnlbd3qs 8ukth
14 Jun 21
Entry into a Material Definitive Agreement
4:08pm
8-K
EX-99.2
1wmf8mmmvfci4kme
6 May 21
Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer
7:08am
8-K
EX-99.2
46wmcyk ntk
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
S-8
EX-23.1
cb2tv8kn6uynpen
17 Mar 21
Registration of securities for employees
4:06pm
S-8
0l80v0 w0dl26dzj9
17 Mar 21
Registration of securities for employees
4:06pm
8-K
EX-99.1
1nvi1
2 Mar 21
Regulation FD Disclosure
8:00am
8-K
EX-10.1
bui06z uu9bg6s
16 Feb 21
Entry into a Material Definitive Agreement
7:10am
424B5
xl8ky98hf7 s7
16 Feb 21
Prospectus supplement for primary offering
7:05am
8-K
EX-10.1
gsgiexykx4gcx3kkwl9
4 Jan 21
Aravive Announces Board Member Transition to Advisory Role
4:11pm